Is 3′-deoxy-3′-18F-fluorothymidine a better marker for tumour response than 18F-fluorodeoxyglucose?

@article{Reske2006Is3A,
  title={Is 3′-deoxy-3′-18F-fluorothymidine a better marker for tumour response than 18F-fluorodeoxyglucose?},
  author={Sven N. Reske and Sandra Deisenhofer},
  journal={European Journal of Nuclear Medicine and Molecular Imaging},
  year={2006},
  volume={33},
  pages={38-43}
}
3′-Deoxy-3′-18F-fluorothymidine (FLT) was developed in 1998 by Shields and co-workers because monitoring of treatment response would be facilitated by imaging agents able to provide measures of tissue and tumour proliferation. Since then, FLT metabolism has been clarified in more detail in cell culture and experimental animal tumour models and also in clinical studies. Recently, FLT has increasingly been used for the assessment of response to anticancer treatment, mainly in tumour xenograft… CONTINUE READING
BETA

Figures, Tables, and Topics from this paper.

Explore Further: Topics Discussed in This Paper

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 54 REFERENCES

Biosynthesis in DNA precursors

  • A Kornberg, TA Baker
  • DNA replication. 2nd ed. New York: W.H. Freeman;
  • 1992
Highly Influential
6 Excerpts

Advanced imaging methods: functional and metabolic imaging

  • H Hricak, O Akin, MS Bradbury, L Lieberman, LH Schwartz, SM. Larson
  • 2005
1 Excerpt

Comparison of18F-FLT PET and18F-FDG PET in esophageal cancer

  • HL van Westreenen, DC Cobben, PL Jager, HM van Dullemen, J Wesseling, PH Elsinga
  • J Nucl Med
  • 2005

Similar Papers

Loading similar papers…